Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Capstone Therapeutics ( (CAPS) ).
Capstone Holding Corp. entered into a securities purchase agreement with an institutional investor on July 29, 2025, authorizing the issuance of senior secured convertible notes with an original principal amount of up to $10,909,885. On August 14, 2025, the company and the buyer agreed to reduce the conversion price of the first issued note from $1.72 to $1.00, effective August 15, 2025, with a conversion limit of $1,363,736 at the new price.
Spark’s Take on CAPS Stock
According to Spark, TipRanks’ AI Analyst, CAPS is a Neutral.
Capstone Therapeutics’ overall stock score reflects significant financial challenges and poor valuation. However, recent strategic acquisitions and positive corporate events provide potential growth opportunities. Technical indicators suggest a neutral to slightly bearish outlook, indicating caution for potential investors.
To see Spark’s full report on CAPS stock, click here.
More about Capstone Therapeutics
Average Trading Volume: 438,722
Technical Sentiment Signal: Sell
Current Market Cap: $7.05M
For detailed information about CAPS stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money